-
Featured
Effective Ketamine Dosages for Treatment-resistant Depression Identified
Ketamine has long been used as a general anesthetic, but more recent research has found it to be effective in rapidly relieving depression symptoms when given at low, subanesthetic doses. New research identifies two optimal dosages.
-
Featured
Ketamine Has Potential Utility for Treating Treatment-Resistant Anxious Depression
Unlike traditional antidepressants, ketamine may be similarly effective in both anxious and nonanxious patients with treatment-resistant depression, according to a secondary analysis of a randomized, controlled clinical trial.
-
Featured
Q&A with Dr. Cristina Cusin: What to Know About Esketamine and Ketamine Treatment
The FDA recently approved Spravato, an intranasal form of esketamine for patients with treatment-resistant depression, which produces improvement hours to days after administration.
-
Chief of Psychiatry, Maurizio Fava, MD, Discusses U.S. News & World Report ranking Mass General #1 for Psychiatry in 2024-25
The Massachusetts General Hospital Department of Psychiatry has been recognized for its exceptional commitment to advancing mental healthcare. Mass General was ranked #1 Psychiatry in the nation for Psychiatry in 2024-25 by U.S. News and World Report.
Ketamine Treatment Contributors
-
Cristina Cusin, MD
Assistant Professor in Psychiatry, Staff Psychiatrist, Depression Clinical and Research Program
Recent Article
Q&A with Dr. Cristina Cusin: What to Know About Esketamine and Ketamine Treatment
-
George Papakostas, MD
Director, Treatment-Resistant Depression Studies, Depression Clinical and Research Program, Massachusetts General Hospital
Recent Article
Ketamine Has Potential Utility for Treating Treatment-Resistant Anxious Depression
-
Maurizio Fava, MD
Psychiatrist-In-Chief; Director, Division of Clinical Research of the MGH Research Institute, Executive Director, Clinical Trials Network and Institute (CTNI), Massachusetts General Hospital, Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School
Recent Article
Propensity Score Weighting Accounts Well for Placebo Response in Two Trials of Medical Therapy for MDD
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.